Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
Pappolla A, Auger C, Sao-Aviles A, Tur C, Rodriguez-Barranco M, Cobo-Calvo Á, Mongay-Ochoa N, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Carbonell-Mirabent P, Carvajal R, Castilló-Justribó J, Braga N, Bollo L, Vidal-Jordana A, Arrambide G, Nos C, Salerno A, Galán I, Comabella M, Sastre-Garriga J, Tintoré M, Rovira A, Montalban X, Río J.
Pappolla A, et al. Among authors: nos c.
Mult Scler. 2024 Jun;30(7):820-832. doi: 10.1177/13524585241240653. Epub 2024 Mar 29.
Mult Scler. 2024.
PMID: 38551315